Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study
- PMID:38056906
- DOI: 10.1002/dta.3622
Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study
Abstract
The acute psychoactive, autonomic, and endocrine effects of the new psychoactive substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 180-228 mg) were investigated in six healthy volunteers (four males, two females) in a non-blinded fashion without placebo. Subjective, cardiovascular, and endocrine responses were compared with two different doses of 3,4-methylenedioxymethamphetamine (MDMA) (75 mg and 125 mg) described in previously published placebo-controlled studies, which used identical outcome measures including Visual Analogue Scales (VAS), the Adjective Mood Rating Scale (AMRS), and the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. MDAI was well tolerated and produced subjective effects comparable with those of 125 mg MDMA. MDAI increased blood pressure similar to 125 mg MDMA but did not increase heart rate or body temperature. MDAI increased cortisol and prolactin levels and could be detected in serum about 20 min post ingestion and remained detectable at least for 4 days. In urine, MDAI was detectable over a period of at least 6 days. Further clinical investigations are warranted to assess whether MDAI could serve as drug with medicinal properties.
Keywords: clinical; entactogens; new psychoactive substances; pharmacokinetics; psychometric.
© 2023 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Similar articles
- Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, Luethi D, Liechti ME.Straumann I, et al.Neuropsychopharmacology. 2024 Dec;50(2):362-371. doi: 10.1038/s41386-024-01972-6. Epub 2024 Aug 23.Neuropsychopharmacology. 2024.PMID:39179638Free PMC article.Clinical Trial.
- Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.Farré M, et al.J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. doi: 10.1124/jpet.107.129056. Epub 2007 Sep 21.J Pharmacol Exp Ther. 2007.PMID:17890444Clinical Trial.
- Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME.Hysek CM, et al.J Pharmacol Exp Ther. 2012 Feb;340(2):286-94. doi: 10.1124/jpet.111.188425. Epub 2011 Oct 27.J Pharmacol Exp Ther. 2012.PMID:22034656Clinical Trial.
- Substance use during the COVID-19 pandemic: What is really happening?Mellos E, Paparrigopoulos T.Mellos E, et al.Psychiatriki. 2022 Mar 28;33(1):17-20. doi: 10.22365/jpsych.2022.072. Epub 2022 Feb 21.Psychiatriki. 2022.PMID:35255473English, Greek, Modern.
- Domperidone.[No authors listed][No authors listed]2025 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–.2025 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–.PMID:30000430Free Books & Documents.Review.
References
REFERENCES
- Brandt SD, King LA, Evans‐Brown M. The new drug phenomenon. Drug Test Anal. 2014;6(7–8):587‐597. doi:10.1002/dta.1686
- Huestis MA, Brandt SD, Rana S, Auwärter V, Baumann MH. Impact of novel psychoactive substances on clinical and forensic toxicology and global public health. Clin Chem. 2017;63(10):1564‐1569. doi:10.1373/clinchem.2017.274662
- Evans‐Brown M, Sedefov R. Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol. 2018;252:3‐49. doi:10.1007/164_2018_160
- Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M. Emergence, diversity, and control of new psychoactive substances: a global perspective. Handb Exp Pharmacol. 2018;252:51‐67. doi:10.1007/164_2018_127
- EMCDDA. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA. EMCDDA, Lisbon. 2011. Available at:https://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europo... [27 June 2020].
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous